AngioDynamics (ANGO) Competitors

Alphatec (NASDAQ:ATEC) and AngioDynamics (NASDAQ:ANGO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, community ranking, earnings, profitability, valuation, dividends and institutional ownership.

Does the media prefer ATEC or ANGO?

In the previous week, Alphatec had 7 more articles in the media than AngioDynamics. MarketBeat recorded 9 mentions for Alphatec and 2 mentions for AngioDynamics. AngioDynamics' average media sentiment score of 1.06 beat Alphatec's score of 0.60 indicating that AngioDynamics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alphatec	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AngioDynamics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, ATEC or ANGO?

Alphatec has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, AngioDynamics has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500.

Does the MarketBeat Community prefer ATEC or ANGO?

AngioDynamics received 33 more outperform votes than Alphatec when rated by MarketBeat users. Likewise, 61.26% of users gave AngioDynamics an outperform vote while only 58.20% of users gave Alphatec an outperform vote.

Company	Underperform	Outperform
Alphatec	Outperform Votes 337 58.20%	Underperform Votes 242 41.80%
AngioDynamics	Outperform Votes 370 61.26%	Underperform Votes 234 38.74%

Is ATEC or ANGO more profitable?

Alphatec has a net margin of -31.06% compared to AngioDynamics' net margin of -79.38%. AngioDynamics' return on equity of -7.26% beat Alphatec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alphatec	-31.06%	-541.39%	-22.99%
AngioDynamics	-79.38%	-7.26%	-4.78%

Do analysts recommend ATEC or ANGO?

Alphatec currently has a consensus target price of $17.89, suggesting a potential upside of 57.33%. AngioDynamics has a consensus target price of $14.00, suggesting a potential upside of 28.56%. Given Alphatec's higher possible upside, research analysts plainly believe Alphatec is more favorable than AngioDynamics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alphatec	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
AngioDynamics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has better valuation and earnings, ATEC or ANGO?

AngioDynamics has lower revenue, but higher earnings than Alphatec. AngioDynamics is trading at a lower price-to-earnings ratio than Alphatec, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alphatec	$642.27M	2.59	-$186.64M	-$1.15	-9.89
AngioDynamics	$283.32M	1.56	-$184.35M	-$1.01	-10.78

Do insiders and institutionals hold more shares of ATEC or ANGO?

66.3% of Alphatec shares are held by institutional investors. Comparatively, 89.4% of AngioDynamics shares are held by institutional investors. 20.9% of Alphatec shares are held by company insiders. Comparatively, 5.4% of AngioDynamics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

AngioDynamics beats Alphatec on 10 of the 18 factors compared between the two stocks.